BV02 (10 mg/kg; i.p.; once daily; 4 days during DSS-induced colitis) enhances Akt activation in the mucosa of colitic mice, increases apoptosis, and decreases cell proliferation, further shortening the colon length[4].
BV02 (10 mg/kg; i.p.; 1 day prior to receiving PTZ) weakens the anti-epileptic effects of LV-14-3-3 and LV-HAP1 in Pentylenetetrazole (PTZ)-induced epileptic rats, increasing seizure severity, shortening latency and increasing generalized tonic clonic (GTC) values per rat[5].
BV02 (3 mg/kg; i.p.; once daily; for 3 days starting 10 days post - infection) reduces the splenic load of B. melitensis in infected mice[6].
